Merck & Company Inc (MRK)vsRevvity Inc. (RVTY)
MRK
Merck & Company Inc
$144.70
-2.49%
HEALTHCARE · Cap: $368.89B
RVTY
Revvity Inc.
$151.60
-3.44%
HEALTHCARE · Cap: $17.72B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 2214% more annual revenue ($67.38B vs $2.91B). RVTY leads profitability with a 8.2% profit margin vs 3.6%. RVTY appears more attractively valued with a PEG of 0.73. RVTY earns a higher WallStSmart Score of 52/100 (C-).
MRK
Hold44
out of 100
Grade: D
RVTY
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-76.6%
Fair Value
$84.66
Current Price
$144.70
$60.04 premium
Intrinsic value data unavailable for RVTY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 4.5B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Trading at 8.5x book value
4.7% revenue growth
ROE of 7.6% — below average capital efficiency
3.6% margin — thin
1.3% revenue growth
1.2% earnings growth
ROE of 3.3% — below average capital efficiency
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : RVTY
The strongest argument for RVTY centers on PEG Ratio, Price/Book. PEG of 0.73 suggests the stock is reasonably priced for its growth.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Bear Case : RVTY
The primary concerns for RVTY are Revenue Growth, EPS Growth, Return on Equity. A P/E of 76.0x leaves little room for execution misses.
Key Dynamics to Monitor
RVTY carries more volatility with a beta of 1.06 — expect wider price swings.
MRK is growing revenue faster at 4.7% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RVTY scores higher overall (52/100 vs 44/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Revvity Inc.
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets globally. The company is headquartered in Waltham, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?